MYC and pancreatic neoplasm: Besides, I-BET762 could promote the sensitivity of pancreatic cancer cells to gemcitabine.163 I-BET762 (30 mg/kg/day for 13 days) also decreased tumor size in mice with pancreatic cancer xenograft and markedly enhanced the effect of gemcitabine on pancreatic cancer xenograft.163 BET inhibitors can suppress several oncogenic pathways other than c-Myc-dependent pathways which can increase their efficacy as chemotherapeutic agents.164